The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity

The oncolytic adenovirus Delta24-RGD represents a new promising therapeutic agent for patients with a malignant glioma and is currently under investigation in clinical phase I/II trials. Earlier preclinical studies showed that Delta24-RGD is able to effectively lyse tumor cells, yielding promising r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleijn, Anne, Kloezeman, Jenneke, Treffers-Westerlaken, Elike, Fulci, Giulia, Leenstra, Sieger, Dirven, Clemens, Debets, Reno, Lamfers, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035348/
https://www.ncbi.nlm.nih.gov/pubmed/24866126
http://dx.doi.org/10.1371/journal.pone.0097495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035348/
https://www.ncbi.nlm.nih.gov/pubmed/24866126
http://dx.doi.org/10.1371/journal.pone.0097495

Ejemplares similares